Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
The first GLP-1 receptor agonist approved for obesity was liraglutide, marketed in the U.S. as Saxenda, in 2014. However, the ...
GLP-1, SGLT2 medications may lower risk of future MI and repeat stroke among stroke survivors: Study
The GLP-1 medications liraglutide and semaglutide, as well as the dual GLP-1 and glucose-independent insulinotropic ...
Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.
The use of weight loss drugs without doctor's supervision is not advisable and can lead to serious side effects and ...
Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...
FDA approved medications included in the study were GLP-1s liraglutide, semaglutide and tirzepatide, and SGLT2s canagliflozin, dapagliflozin, empagliflozin and ertugliflozin. Here are five things to ...
MedPage Today on MSN1d
ObesityWeek Roundup: Patients More Likely to Ration Weight-Loss DrugsSAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...
Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, ...
As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback